PT2697243T - Modulação da expressão do transdutor de sinal e ativador da transcrição 3 (stat3) - Google Patents

Modulação da expressão do transdutor de sinal e ativador da transcrição 3 (stat3)

Info

Publication number
PT2697243T
PT2697243T PT12763390T PT12763390T PT2697243T PT 2697243 T PT2697243 T PT 2697243T PT 12763390 T PT12763390 T PT 12763390T PT 12763390 T PT12763390 T PT 12763390T PT 2697243 T PT2697243 T PT 2697243T
Authority
PT
Portugal
Prior art keywords
stat3
activator
transcription
modulation
expression
Prior art date
Application number
PT12763390T
Other languages
English (en)
Inventor
E Swayze Eric
M Freier Susan
A Macleod Robert
Kim Youngsoo
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of PT2697243T publication Critical patent/PT2697243T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
PT12763390T 2011-04-01 2012-03-30 Modulação da expressão do transdutor de sinal e ativador da transcrição 3 (stat3) PT2697243T (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161471001P 2011-04-01 2011-04-01
US201161471045P 2011-04-01 2011-04-01
US201161471035P 2011-04-01 2011-04-01
US201161471015P 2011-04-01 2011-04-01
US201161558308P 2011-11-10 2011-11-10
US201161558316P 2011-11-10 2011-11-10

Publications (1)

Publication Number Publication Date
PT2697243T true PT2697243T (pt) 2019-01-29

Family

ID=46932413

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12763390T PT2697243T (pt) 2011-04-01 2012-03-30 Modulação da expressão do transdutor de sinal e ativador da transcrição 3 (stat3)

Country Status (33)

Country Link
US (4) US8816056B2 (pt)
EP (2) EP2697243B1 (pt)
JP (1) JP5943993B2 (pt)
KR (2) KR102050469B1 (pt)
CN (2) CN107012144A (pt)
AU (1) AU2012236206C1 (pt)
BR (1) BR112013024768B1 (pt)
CA (1) CA2831915C (pt)
CL (1) CL2013002773A1 (pt)
CO (1) CO6821885A2 (pt)
CY (1) CY1121460T1 (pt)
DK (1) DK2697243T3 (pt)
DO (1) DOP2013000216A (pt)
EA (2) EA029317B1 (pt)
EC (1) ECSP13012909A (pt)
ES (1) ES2709495T3 (pt)
GT (1) GT201300232A (pt)
HR (1) HRP20182169T1 (pt)
HU (1) HUE042173T2 (pt)
IL (2) IL228569A (pt)
LT (1) LT2697243T (pt)
ME (1) ME03317B (pt)
MX (1) MX340086B (pt)
MY (1) MY163004A (pt)
NI (1) NI201300101A (pt)
PE (2) PE20142463A1 (pt)
PL (1) PL2697243T3 (pt)
PT (1) PT2697243T (pt)
RS (1) RS58489B1 (pt)
SG (1) SG193504A1 (pt)
SI (1) SI2697243T1 (pt)
WO (1) WO2012135736A2 (pt)
ZA (1) ZA201308153B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2697243T3 (pl) 2011-04-01 2019-05-31 Ionis Pharmaceuticals Inc Modulacja ekspresji przekaźnika sygnału i aktywatora transkrypcji 3 (stat3)
WO2013149086A1 (en) 2012-03-28 2013-10-03 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHODS OF MONITORING C9ORF72 EXPRESSION
EP2906258A4 (en) 2012-10-15 2016-08-10 Ionis Pharmaceuticals Inc COMPOSITIONS FOR MODULATING THE EXPRESSION OF C90RF72
EP3483273A1 (en) * 2012-10-31 2019-05-15 Ionis Pharmaceuticals, Inc. Cancer treatment
PT2992098T (pt) 2013-05-01 2019-07-05 Ionis Pharmaceuticals Inc Composições e métodos para modular a expressão de hbv e ttr
ES2787600T3 (es) * 2013-07-02 2020-10-16 Ionis Pharmaceuticals Inc Moduladores del receptor de la hormona del crecimiento
EP3693472A1 (en) 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
EP4166667A3 (en) 2013-10-11 2023-08-02 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
SI3137605T1 (sl) 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
PE20170010A1 (es) 2014-05-01 2017-03-04 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion del factor b del complemento
CA2942570A1 (en) 2014-05-01 2015-11-05 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
HUE043227T2 (hu) 2014-10-24 2019-08-28 Astrazeneca Ab Kombináció
ES2791995T3 (es) 2015-04-16 2020-11-06 Ionis Pharmaceuticals Inc Composiciones para modular la expresión de C90RF72
CN107980001B (zh) 2015-07-02 2021-12-17 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
SG10202006563PA (en) 2015-07-10 2020-08-28 Ionis Pharmaceuticals Inc Modulators of diacyglycerol acyltransferase 2 (dgat2)
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
AU2016349625B2 (en) 2015-11-06 2022-07-07 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
EP3372233B1 (en) 2015-11-06 2021-07-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2017188898A1 (en) 2016-04-29 2017-11-02 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
CN105985961B (zh) * 2016-07-22 2019-01-29 广西师范大学 抑制EGFR基因表达的siRNA及其应用
EP3512525B1 (en) 2016-09-16 2022-07-27 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CA3058018A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
GB2574793B (en) * 2018-05-01 2022-09-28 Flexenable Ltd Organic liquid crystal display device with one or more oxygen permeable films
TW202023573A (zh) * 2018-09-19 2020-07-01 美商Ionis製藥公司 Pnpla3表現之調節劑
WO2021030768A1 (en) * 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with stat3-antisense oligonucleotides
JP2022550783A (ja) 2019-09-30 2022-12-05 アストラゼネカ・アクチエボラーグ 併用処置
EP4058152A4 (en) * 2019-11-14 2024-05-08 The Board of Regents of the University of Oklahoma PROSTATE CANCER TREATMENTS USING OLIGONUCLEOTIDES INTERFERENCE
CN114908094B (zh) * 2022-05-31 2024-03-12 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1993005182A1 (en) 1991-09-05 1993-03-18 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
EP0676469A3 (en) 1994-04-04 1998-03-25 Tadamitsu Kishimoto Transcription Factor APRF
CA2190471A1 (en) 1994-05-16 1995-11-23 Carlos Eduardo Lopez-Nieto Processes, apparatus and compositions for characterizing nucleotide sequences
EP0717110A1 (en) 1994-11-22 1996-06-19 Association Francaise Contre Les Myopathies LGMD gene
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
WO1998030688A1 (fr) 1997-01-10 1998-07-16 Tadamitsu Kishimoto Nouvelle proteine de regulation de la fonction stat
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
EP1261697B1 (en) 1999-07-09 2004-07-28 Université de Liège Cold-active beta galactosidase, the process for its preparation and the use thereof
US6248586B1 (en) 1999-12-17 2001-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of PKA catalytic subunit C-alpha expression
ATE547095T1 (de) 2001-05-11 2012-03-15 Isis Pharmaceuticals Inc Antisense-permeationsverstärker
US20050196781A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
JP2005516586A (ja) 2001-07-20 2005-06-09 ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ 癌の処置に対する遺伝子標的を同定するための試薬および方法
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
ES2382807T3 (es) 2003-08-28 2012-06-13 Takeshi Imanishi Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación
AU2004274021B2 (en) 2003-09-18 2009-08-13 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
CN1733916A (zh) * 2005-07-01 2006-02-15 中国人民解放军第三军医大学 抑制Stat3基因表达的siRNA及其制备方法
CN100357436C (zh) * 2005-07-01 2007-12-26 中国人民解放军第三军医大学 抑制Stat3基因表达的siRNA及其制备方法
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
DK2066684T3 (da) 2006-05-11 2012-10-22 Isis Pharmaceuticals Inc 5´-Modificerede bicycliske nukleinsyreanaloge
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008109494A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009039189A2 (en) * 2007-09-17 2009-03-26 Intradigm Corporation Compositions comprising stat3 sirna and methods of use thereof
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
PL2697243T3 (pl) 2011-04-01 2019-05-31 Ionis Pharmaceuticals Inc Modulacja ekspresji przekaźnika sygnału i aktywatora transkrypcji 3 (stat3)
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
EP3483273A1 (en) 2012-10-31 2019-05-15 Ionis Pharmaceuticals, Inc. Cancer treatment
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Also Published As

Publication number Publication date
EP3466960A2 (en) 2019-04-10
US20120277284A1 (en) 2012-11-01
CL2013002773A1 (es) 2014-04-04
US10479993B2 (en) 2019-11-19
MX2013011423A (es) 2014-04-30
BR112013024768A2 (pt) 2018-06-05
ECSP13012909A (es) 2013-12-31
US20160348104A1 (en) 2016-12-01
EP2697243B1 (en) 2018-10-31
CA2831915A1 (en) 2012-10-04
HUE042173T2 (hu) 2019-06-28
JP2014511686A (ja) 2014-05-19
CY1121460T1 (el) 2020-05-29
LT2697243T (lt) 2019-04-10
IL228569A (en) 2017-12-31
EA029317B1 (ru) 2018-03-30
EP3466960A3 (en) 2019-04-24
ZA201308153B (en) 2016-01-27
PL2697243T3 (pl) 2019-05-31
MY163004A (en) 2017-07-31
NI201300101A (es) 2014-07-08
RS58489B1 (sr) 2019-04-30
MX340086B (es) 2016-06-24
DOP2013000216A (es) 2013-12-15
SI2697243T1 (sl) 2019-05-31
CN107012144A (zh) 2017-08-04
US9359608B2 (en) 2016-06-07
CO6821885A2 (es) 2013-12-31
EA201792185A2 (ru) 2018-06-29
PE20142463A1 (es) 2015-01-22
EP2697243A2 (en) 2014-02-19
SG193504A1 (en) 2013-10-30
IL228569A0 (en) 2013-12-31
CN103562215A (zh) 2014-02-05
DK2697243T3 (en) 2019-02-11
NZ616036A (en) 2015-09-25
IL255858A (en) 2018-01-31
AU2012236206A1 (en) 2013-05-02
BR112013024768B1 (pt) 2022-02-08
KR102050469B1 (ko) 2019-12-02
HRP20182169T1 (hr) 2019-04-19
KR20190092590A (ko) 2019-08-07
US20200385716A1 (en) 2020-12-10
US20140336237A1 (en) 2014-11-13
AU2012236206B2 (en) 2015-09-17
WO2012135736A2 (en) 2012-10-04
KR20140027205A (ko) 2014-03-06
GT201300232A (es) 2015-02-11
ES2709495T3 (es) 2019-04-16
CN103562215B (zh) 2017-04-26
ME03317B (me) 2019-10-20
CA2831915C (en) 2021-01-12
JP5943993B2 (ja) 2016-07-05
US8816056B2 (en) 2014-08-26
EA201792185A3 (ru) 2018-10-31
PE20181518A1 (es) 2018-09-21
EP2697243A4 (en) 2015-04-01
EA201391329A1 (ru) 2014-07-30
AU2012236206C1 (en) 2018-03-08
WO2012135736A3 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
HRP20182169T1 (hr) Modulacija ekspresije transduktora signala i aktivatora transkripcije 3 (stat3)
IL263020A (en) New modulators and methods of use
EP2912514A4 (en) HEAD-MOUNTED DISPLAY AND METHOD FOR GENERATING AN AUDIO SIGNAL THEREWITH
IL247595A0 (en) New modulators and methods of use
EP2663093A4 (en) SOUND TRANSFORMER AND MICROPHONE THEREWITH
ZA201100536B (en) Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
SG10201601792UA (en) Novel modulators and methods of use
EP2677676A4 (en) Method of signal generation and signal generating device
AU2012218953A1 (en) Method of signal generation and signal generating device
EP2503887A4 (en) SUBSTITUTED BIARYL DERIVATIVES AND METHODS OF USE
GB201112676D0 (en) Method of sound analysis and associated sound synthesis
EP2556016A4 (en) Frequency synthesis apparatus and method
HK1184791A1 (zh) 細胞凋亡抑制劑及其用途
GB201217867D0 (en) Acoustic transducer with a liquid-filled porous medium backing and methods of making and using same
SI2576556T1 (sl) Postopek za sintezo karbonukleozida in intermediatov za uporabo v tem postopku
PL2694532T3 (pl) Pochodne aureobasidin i sposoby syntezy
ZA201306550B (en) Method of outputting audio signal and audio signal output apparatus using the method
EP2968576A4 (en) Synthesis of ent-progesterone and intermediates thereof
GB2499538B (en) Acoustic transducers with dynamic frequency range
DE112011104192A5 (de) Elektroakustische Wandleranordnung und Betriebsverfahren dafür
TH107731B (th) วิธีการและเครื่องสำหรับขับทรานสดิวเซอร์ของอุปกรณ์ที่ใช้สูด
PL393381A1 (pl) Sposób i układ do regulacji amplitudy sygnału wyjściowego z układu cyfrowego syntezy częstotliwości